Cardio inCode-Score for Cardiovascular Risk Assessment (GENinCode)
Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality worldwide, accounting for nearly one-third of global deaths. While traditional risk factors such as hypertension, hyperlipidemia, diabetes, and smoking play critical roles, approximately 50% of cardiovascular events are influenced by genetic predisposition. The presence of inherited variants significantly contributes to coronary events, underscoring the importance of genetic assessment in risk prediction.
The CARDIO inCode-Score (cic-score) is a genetic risk assessment test that utilizes polymerase chain reaction (PCR) technology to genotype 12 validated single nucleotide polymorphisms (SNPs) across multiple genes involved in cardiovascular regulation. The assay integrates these findings into a Genetic Risk Score (GRS), which complements traditional risk factors to stratify patients into lower- or higher-risk categories for cardiovascular disease.
Clinical studies demonstrate that patients with acute myocardial infarction often exhibit a significantly higher GRS compared to those without events. By refining risk stratification, the cic-score supports earlier interventions, such as lifestyle modification, pharmacotherapy, or closer monitoring, to reduce the likelihood of future coronary events.
- Aids in predicting future cardiovascular disease
- Assesses the likelihood of major acute coronary events, including myocardial infarction
- Supports personalized management strategies in both preventive and clinical cardiology
Not applicable (risk reported as a categorical Genetic Risk Score)
Whole blood, EDTA, buccal swab.
Stability
- Ambient: 72 hours
- Refrigerated: 7 days
- Frozen: 30 days
- Glob Cardiol Sci Pract. 2021 Dec 31;2021(4):e202131. [PMID: 36185161]
- Circ Cardiovasc Genet. 2016 Dec;9(6):531-540. [PMID: 27780846]
- Rev Esp Cardiol (Engl Ed). 2020 Aug;73(8):623-631. [PMID: 31629691]
- Atherosclerosis. 2012 Jun;222(2):456-63. [PMID: 22521901]